Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.

Desmetramadol a safer, more effective analgesic than tramadol

19 Oct 2019
Healthcare providers to educate the public and promote awareness of the consequences of paracetamol overdose

Desmetramadol is able to provide the analgesic benefits of tramadol without the associated metabolic liabilities, according to a recent series of trials.

The study involved two consecutive randomized, double-blind, three-period cross-over, placebo- and active comparator-controlled trials. Researchers randomly assigned 103 healthy participants to receive 50 mg tramadol and 20 mg desmetramadol either with (trial A; n=43; mean age, 28.4±8.0 years; 100 percent male) or without (trial B; n=60; mean age, 28.0±6.8 years; 70 percent male) cotreatment with paroxetine.

In trial A, participants treated with tramadol (mean change, –0.46±0.19; p=0.022) and desmetramadol (mean change, –0.60±0.15; p=0.0005) exhibited significant decreases in average cold-induced pain perception at 30 seconds relative to placebo controls. No significant differences were reported when the two active treatments were compared against each other (p=0.47).

In the male subgroup of trial B, tramadol failed to produce significantly better analgesia relative to placebo (p=0.90), while desmetramadol significantly outperformed both tramadol (p=0.003) and placebo (p=0.036).

Moreover, in the presence of paroxetine, desmetramadol provided 44-percent longer pain tolerance duration relative to placebo than did tramadol.

In trial A, tramadol and desmetramadol showed comparable safety profiles. Cotreatment with paroxetine seemed to result in fewer adverse events.

“Desmetramadol thus obviates the metabolic liabilities of tramadol while preserving its safety profile, because it does not rely on the activity of CYP enzymes for its activity,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.